Free Shipping On Orders Over $1,000!

Contact us at 1.800.501.7654 or info@biossusa.com

MenuSearch

PD-L1 (6C8) Monoclonal Antibody

Lane 1: full-length PD-L1 transfected 293T; Lane 2: untransfected 293T, probed with PD-L1 (6C8) Monoclonal Antibody, Unconjugated (bsm-58003R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Lane 1: full-length PD-L1 transfected 293T; Lane 2: untransfected 293T, probed with PD-L1 (6C8) Monoclonal Antibody, Unconjugated (bsm-58003R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Flow cytometric analysis of 293F cells expressing PD-L1 probed with PD-L1 (6C8) Monoclonal Antibody, unconjugated (bsm-58003R) at 1:100 dilution (red), compared control IgG staining (blue).
Flow cytometric analysis of 293F cells expressing PD-L1 probed with PD-L1 (6C8) Monoclonal Antibody, unconjugated (bsm-58003R) at 1:100 dilution (red), compared control IgG staining (blue).

Applications

  • WB
  • FCM

Reactivity

  • Human
Overview
Catalog # bsm-58003R
Product Name PD-L1 (6C8) Monoclonal Antibody
Applications WB, FCM
Reactivity Human
Specifications
Conjugation Unconjugated
Host Rabbit
Source Recombinant human PD-L1 extracellular domain
Clonality Monoclonal
Clone # 6C8
Isotype IgG
Concentration Not Determined
Purification Purified by Protein A.
Storage Buffer 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C for 12 months.
Target
Gene ID 29126
Swiss Prot Q9NZQ7
Synonyms Programmed cell death 1 ligand 1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1; Programmed death ligand 1
Background Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).
Application Dilution
WB 1:300-5000
FCM 1:20-100

Search our catalog of hundreds of thousands of products